Effect of melatonin in children with neurodevelopmental disabilities and sleep disorders.

Autor: Al Twaijri WA; Pediatric Neurology Division, Department of Pediatric, King Abdullah Children Specialist Hospital, National Guard Health Affairs, Riyadh, Saudi Arabia., Ba Armah D; Pediatric Neurology Division, Department of Pediatric, King Abdullah Children Specialist Hospital, National Guard Health Affairs, Riyadh, Saudi Arabia., Bin Sabbar N; Pediatric Neurology Division, Department of Pediatric, King Abdullah Children Specialist Hospital, National Guard Health Affairs, Riyadh, Saudi Arabia., Aldebasi T; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia., Shaheen N; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia., Al Bekairy AKS; Pharmaceutical Care Services, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia., Al-Jeraisy M; King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia.; Pharmaceutical Care Services, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.; Pediatric Clinical Pharmacy, King Abdullah Children Specialist Hospital, National Guard Health Affairs, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: Journal of family medicine and primary care [J Family Med Prim Care] 2022 Jan; Vol. 11 (1), pp. 299-304. Date of Electronic Publication: 2022 Jan 31.
DOI: 10.4103/jfmpc.jfmpc_1839_21
Abstrakt: Objectives: The aim of this study is to assess the efficacy and side effects of melatonin use in a population of children with neurodevelopmental disabilities who had sleep disorders.
Methods: This is a cross-sectional study conducted in the pediatric neurology clinic at King Abdulaziz Medical City. A designed questionnaire was given to the parents to inquire about the sleep characteristics of their children before and after using melatonin. The patients' demographic data were collected and different parameters before and after starting melatonin were compared. Categorical variables were summarized and reported in terms of frequency and percent (n%). Continuous variables were reported in terms of mean and standard deviation.
Results: A total of 23 patients were enrolled in our study, of which 15 (65.22%) were male. The mean age was 5.83 ± 3.07 years. For melatonin dose, 9 (39.13%) received 1 mg, 8 (34.78%) received 2 mg, and 6 (26.09%) received over 3 mg. Regarding melatonin duration of use, 7 (30.43%) received melatonin for 0 to 6 months, 7 (30.43%) received it for 7 to 12 months, and 9 (39.13%) received it for over a year. Significant differences were observed in time taken to fall asleep ( P =0.046), the number of times the child woke up at night ( P =0.071), total sleep time within 24 hours ( P =.011), and time taken to wake up ( P =.007), while no significant difference was observed in the number of naps taken during the daytime ( P =.801). There were no major side effects reported.
Conclusion: Melatonin had a significant impact on total sleep time and quality during the pre and post assessment of children with neurodevelopmental disabilities and sleep disorders.
Competing Interests: There are no conflicts of interest.
(Copyright: © 2022 Journal of Family Medicine and Primary Care.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje